InSymbiosis’ Investment Vehicle (formalized in 2016 as InSynchrony Ventures Inc.) tactically combines InSymbiosis’ successful business model with our desire to accelerate promising early stage drug assets towards clinical proof of concept and strategic exits.Contact Our Investment Team
As investors, we are opportunistic and we therefore do not have a particular therapeutic bias. We are interested in meeting companies with therapeutic products in development that have achieved a minimum of animal proof of concept and have a clearly defined drug development plan and commercial exit strategy.
MHB Labs is a Boston based biopharmaceutical start-up founded by leading men’s health physicians seeking to develop superior treatments for hypogonadism (low testosterone). They have developed AndroSphere, the first extended release form of human chorionic gonadotropin, which has attractive features that could make it a market leader and a new standard for the treatment of low testosterone.
Genoa Pharmaceuticals is a San Diego-based pharmaceutical company developing improved therapies for the treatment of Idiopathic Pulmonary Fibrosis.